Sushen Pharmasciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Profit Growth -20.83%
- Ebitda -40.00%
- Net Worth -4.60%
- Total Assets 1.20%
About Sushen Pharmasciences
Sushen Pharmasciences Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 October 2009 and has a history of 15 years and four months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Aman Kulabkar and Tapan Shah serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24294GJ2009PTC058399
- Company No.
058399
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Oct 2009
- Date of AGM
06 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc-Ahmedabad
Industry
Who are the key members and board of directors at Sushen Pharmasciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tapan Shah  | Director | 21-Dec-2018 | Current |
| Aman Kulabkar | Director | 21-Dec-2018 | Current |
Financial Performance of Sushen Pharmasciences.
Sushen Pharmasciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 20.83% decrease in profit. The company's net worth dipped by a decrease of 4.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sushen Pharmasciences?
In 2020, Sushen Pharmasciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sushen Medicamentos Private LimitedAman Kulabkar is a mutual person
Dmk Ventures Private LimitedTapan Shah is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sushen Pharmasciences?
Unlock and access historical data on people associated with Sushen Pharmasciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sushen Pharmasciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sushen Pharmasciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
